Compass Pathways Plc ADR
Uždarymo kaina
12.49 -1.26
Apžvalga
Akcijų kainos pasikeitimas
24 val.
Min
12.33
Max
13.48
Pajamos | 185M 91M |
|---|---|
Pelnas, tenkantis vienai akcijai | -0.3 |
Darbuotojai | 156 |
EBITDA | 139M 93M |
Rekomendacijos | Stiprus pirkimas |
|---|---|
12 mėnesių prognozė | +85.77% upside |
Kitas uždarbis | 2026-07-30 |
|---|
Rinkos kapitalizacija | 428M 1.7B |
|---|---|
Ankstesnė atidarymo kaina | 13.75 |
Ankstesnė uždarymo kaina | 12.49 |
Compass Pathways Plc ADR Grafikas
Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.
Apie bendrovę Compass Pathways Plc ADR
COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom.
